Haemophilus influenzae b polysaccharide-tetanus conjugate

DB15876ApprovedInvestigationalVaccines

Haemophilus influenzae b polysaccharide-tetanus conjugate: Overview.

First approval
European Union, 2021
Also known as
Haemophilus influenzae type b polysaccharide conjugated to tetanus protein · Haemophilus influenzae type b polysaccharide conjugated to the tetanus protein
Brand names
  • Hexacima

What you can answer from here — as of March 06, 2025

66Clinical trialsPhase, status and sponsor resolved per trial
Sign in
1Structured indicationCondition, population, route and combination as fields, not prose
Sign in
53Marketed productsAcross 6 countries and 10 labellers
Sign in

Which other approved drugs treat the same conditions as Haemophilus influenzae b polysaccharide-tetanus conjugate, and which companies have late-stage candidates in those indications?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In